This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Rain Oncology Stock (NASDAQ:RAIN) 30 days 90 days 365 days Advanced Chart Get Rain Oncology alerts:Sign Up Key Stats Today's Range$2.80▼$3.2750-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32Volume12,534 shsAverage Volume32,376 shsMarket Capitalization$15.51 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More… Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Stock News Headlines'AI Can Detect Cancer, But Bengaluru Still Can’t Handle Rain?' Investor's Viral Rant Sparks DebateMay 21, 2025 | msn.comThousands brave rainy weather for Race For Hope to fund brain cancer researchMay 9, 2025 | msn.comDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. June 4, 2025 | Golden Portfolio (Ad)10-year-old cancer survivor rings bell, throws first pitch at Space Cowboys gameMay 3, 2025 | msn.comLead singer for popular U.K. rock band dies at 66May 1, 2025 | msn.comMike Peters Dies: The Alarm’s Frontman Was 66May 1, 2025 | msn.comToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comSee More Headlines RAIN Stock Analysis - Frequently Asked Questions How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.20) EPS for the quarter. When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an IPO on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO. Who are Rain Oncology's major shareholders? Top institutional investors of Rain Oncology include Polar Asset Management Partners Inc. (0.52%) and Apollo Management Holdings L.P. (0.43%). Insiders that own company stock include Bvf Partners L P/Il, Boxer Capital, Llc, Franklin M Berger and Paul T Dacier. View institutional ownership trends. What other stocks do shareholders of Rain Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and Company Calendar Last Earnings5/15/2025Today6/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:RAIN CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-9.51% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.38 per share Price / Cash Flow7.41 Book Value($0.69) per share Price / Book-4.06Miscellaneous Outstanding Shares5,540,000Free Float4,574,000Market Cap$15.51 million OptionableNo Data Beta-0.11 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:RAIN) was last updated on 6/4/2025 by MarketBeat.com Staff From Our PartnersThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredFPV Drone Innovator Secures Major Defense ContractIn May, Ukraine launched Operation Spider Web - a 117-drone FPV swarm that devastated Russian fuel depots and ...The Tomorrow Investor | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rain Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.